EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Astrocyte-derived extracellular vesicle phosphorylated TDP-43 as a blood-based biomarker for amyotrophic lateral sclerosis

Tanya H Butt, Madeleine Strait, Lina Marcinczyk, Grace Katz, Vrinda Kalia, Cherine Jaafar, Roheeni Saxena, Adnan Divjan, Brianna Saglimbeni, Marfred E Munoz Umanes, Eva Tipps, Moon Han und 7 weitere

Neurobiology of Disease · 2026

DOI: 10.1016/j.nbd.2026.107601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurobiology of Disease, 2026. Verfasst von Tanya H Butt und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: tanyahbutt@…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Extracellular Vesicles, DNA-Binding Proteins, Astrocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIEHS NIH HHS, ATSDR CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by central nervous system (CNS) neuroglial TAR DNA-binding protein 43 (TDP-43) pathology in ∼90-95% of cases. Non-invasive biomarkers are critically needed to reduce diagnostic delay, enable patient stratification, and assess treatment efficacy in clinical trials. Astrocyte-derived extracellular vesicles (ADEVs) represent promising CNS liquid biopsy biomarkers, given astrocyte involvement in ALS pathogenesis and the ability of ADEVs to cross the blood-brain barrier and carry TDP-43. Here, we assessed the diagnostic performance of TDP-43 and its hyperphosphorylated pathological form, phospho-Ser409 (pTDP-43), quantified in ADEVs, for distinguishing ALS cases from matched healthy controls. ADEVs were immunoisolated from whole blood (n = 76) and plasma (n = 86) across three ALS biorepositories/cohorts. ADEV quality and enrichment were validated in accordance with minimal information for studies of extracellular vesicles guidelines, and protein levels were normalized by ratio to tetraspanin cluster of differentiation 81 (CD81). Diagnostic accuracy was evaluated by logistic regression and random forest models with cross-validation, adjusting for age and sex across 100 random seeds. Plasma ADEV pTDP-43/CD81 ratio best predicted ALS case status, with a mean AUC of 0.89 (95% CI: 0.75-0.99) from logistic models, corresponding to a mean sensitivity and specificity of 87% and 89%, respectively, and a mean AUC of 0.86 (95% CI: 0.82-0.90) from random forest models. Although the specificity of ADEV pTDP-43 relative to disease mimics and associations with disease progression require further investigation, these findings support its potential as a biomarker candidate for ALS and for patient stratification in TDP-43-targeted clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisExtracellular VesiclesDNA-Binding ProteinsAstrocytesHumansFemaleMaleBiomarkersPhosphorylationMiddle AgedAged

Stichwörter der Autor:innen

Amyotrophic lateral sclerosisAstrocytesExtracellular vesiclesTDP-43pTDP-43

Substanzen

DNA-Binding ProteinsBiomarkersTARDBP protein, human

Autor:innen und Institutionen

  • Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: tanyahbutt@gmail.com.
  • Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Office of Analytics and Innovation, Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
  • Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA; Center for Motor Neuron Biology and Disease, Columbia University, New York, NY, USA.

Förderung

  • NCATS NIH HHS
  • NIEHS NIH HHS
  • ATSDR CDC HHS
  • National Institute of Environmental Health Sciences
  • Centers for Disease Control and Prevention
  • National Center for Advancing Translational Sciences
  • Agency for Toxic Substances and Disease Registry

Zitieren

APA

Butt, T. H., Strait, M., Marcinczyk, L., Katz, G., Kalia, V., Jaafar, C., Saxena, R., Divjan, A., Saglimbeni, B., Munoz Umanes, M. E., Tipps, E., Han, M., Mehta, P., Lee, I., Mitsumoto, H., Factor-Litvak, P., Shneider, N. A., Kioumourtzoglou, M. A., & Re, D. B. (2026). Astrocyte-derived extracellular vesicle phosphorylated TDP-43 as a blood-based biomarker for amyotrophic lateral sclerosis. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2026.107601

Vancouver

Butt TH, Strait M, Marcinczyk L, Katz G, Kalia V, Jaafar C, et al. Astrocyte-derived extracellular vesicle phosphorylated TDP-43 as a blood-based biomarker for amyotrophic lateral sclerosis. Neurobiology of Disease. 2026. doi:10.1016/j.nbd.2026.107601

BibTeX
@article{Butt2026,
  author = {Butt, Tanya H and Strait, Madeleine and Marcinczyk, Lina and Katz, Grace and Kalia, Vrinda and Jaafar, Cherine and Saxena, Roheeni and Divjan, Adnan and Saglimbeni, Brianna and Munoz Umanes, Marfred E and Tipps, Eva and Han, Moon and Mehta, Paul and Lee, Ikjae and Mitsumoto, Hiroshi and Factor-Litvak, Pam and Shneider, Neil A and Kioumourtzoglou, Marianthi-Anna and Re, Diane B},
  title = {Astrocyte-derived extracellular vesicle phosphorylated TDP-43 as a blood-based biomarker for amyotrophic lateral sclerosis},
  journal = {Neurobiology of Disease},
  year = {2026},
  doi = {10.1016/j.nbd.2026.107601}
}
Kostenlos starten →